JP2023533658A5 - - Google Patents

Info

Publication number
JP2023533658A5
JP2023533658A5 JP2022574594A JP2022574594A JP2023533658A5 JP 2023533658 A5 JP2023533658 A5 JP 2023533658A5 JP 2022574594 A JP2022574594 A JP 2022574594A JP 2022574594 A JP2022574594 A JP 2022574594A JP 2023533658 A5 JP2023533658 A5 JP 2023533658A5
Authority
JP
Japan
Prior art keywords
pharmaceutical composition
composition according
protein
seq
subject
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2022574594A
Other languages
English (en)
Japanese (ja)
Other versions
JP2023533658A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/AU2021/050568 external-priority patent/WO2021243424A1/en
Publication of JP2023533658A publication Critical patent/JP2023533658A/ja
Publication of JP2023533658A5 publication Critical patent/JP2023533658A5/ja
Pending legal-status Critical Current

Links

JP2022574594A 2020-06-04 2021-06-07 急性呼吸窮迫症候群を治療又は予防する方法 Pending JP2023533658A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
AU2020901843 2020-06-04
AU2020901843A AU2020901843A0 (en) 2020-06-04 Method of treating or preventing acute respiratory distress syndrome
PCT/AU2021/050568 WO2021243424A1 (en) 2020-06-04 2021-06-07 Method of treating or preventing acute respiratory distress syndrome

Publications (2)

Publication Number Publication Date
JP2023533658A JP2023533658A (ja) 2023-08-04
JP2023533658A5 true JP2023533658A5 (cg-RX-API-DMAC7.html) 2024-06-12

Family

ID=78830044

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2022574594A Pending JP2023533658A (ja) 2020-06-04 2021-06-07 急性呼吸窮迫症候群を治療又は予防する方法

Country Status (8)

Country Link
US (1) US12583929B2 (cg-RX-API-DMAC7.html)
EP (1) EP4161576A4 (cg-RX-API-DMAC7.html)
JP (1) JP2023533658A (cg-RX-API-DMAC7.html)
KR (1) KR20240008231A (cg-RX-API-DMAC7.html)
CN (1) CN115768475A (cg-RX-API-DMAC7.html)
AU (1) AU2021285088A1 (cg-RX-API-DMAC7.html)
CA (1) CA3175686A1 (cg-RX-API-DMAC7.html)
WO (1) WO2021243424A1 (cg-RX-API-DMAC7.html)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2024003788A1 (en) * 2022-06-29 2024-01-04 Novocure Gmbh Treating acute respiratory distress syndrome with alternating electric fields

Family Cites Families (75)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4196265A (en) 1977-06-15 1980-04-01 The Wistar Institute Method of producing antibodies
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
US5807715A (en) 1984-08-27 1998-09-15 The Board Of Trustees Of The Leland Stanford Junior University Methods and transformed mammalian lymphocyte cells for producing functional antigen-binding protein including chimeric immunoglobulin
US4676980A (en) 1985-09-23 1987-06-30 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Target specific cross-linked heteroantibodies
US5225539A (en) 1986-03-27 1993-07-06 Medical Research Council Recombinant altered antibodies and methods of making altered antibodies
FI903489A7 (fi) 1988-11-11 1990-07-10 Medical Res Council Yhden osan sisältävät ligandit, näitä ligandeja sisältävät reseptorit, menetelmiä niiden valmistamiseksi sekä ligandien ja reseptorien käytt ö
US5530101A (en) 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
IE66494B1 (en) 1989-09-26 1996-01-10 Immunex Corp Granulocyte-colony stimulating factor receptors
ATE318832T1 (de) 1990-06-11 2006-03-15 Gilead Sciences Inc Verfahren zur vervendung von nukleinsäureliganden
US5270163A (en) 1990-06-11 1993-12-14 University Research Corporation Methods for identifying nucleic acid ligands
PT1024191E (pt) 1991-12-02 2008-12-22 Medical Res Council Produção de auto-anticorpos a partir de reportórios de segmentos de anticorpo e exibidos em fagos
AU3691093A (en) 1992-04-14 1993-10-21 Hybritech Incorporated Methods of inhibiting the growth of multidrug resistant tumors
DE69334275D1 (de) 1992-08-21 2009-05-20 Univ Bruxelles Immunoglobuline ohne Leichtkette
CA2145278C (en) 1992-09-25 2009-03-10 Commonwealth Scientific And Industrial Research Organisation Target binding polypeptide
AUPM375194A0 (en) 1994-02-08 1994-03-03 Ludwig Institute For Cancer Research Cytokine receptor interactive molecules
US5731168A (en) 1995-03-01 1998-03-24 Genentech, Inc. Method for making heteromultimeric polypeptides
AUPO591797A0 (en) 1997-03-27 1997-04-24 Commonwealth Scientific And Industrial Research Organisation High avidity polyvalent and polyspecific reagents
EP0859841B1 (en) 1995-08-18 2002-06-19 MorphoSys AG Protein/(poly)peptide libraries
ATE374248T1 (de) 1996-06-27 2007-10-15 Vlaams Interuniv Inst Biotech Antikörpermoleküle, die spezifisch mit dem aktiven zentrum oder dem aktiven spalt eines zielmoleküls interagieren
DE19742706B4 (de) 1997-09-26 2013-07-25 Pieris Proteolab Ag Lipocalinmuteine
US6506559B1 (en) 1997-12-23 2003-01-14 Carnegie Institute Of Washington Genetic inhibition by double-stranded RNA
AUPP221098A0 (en) 1998-03-06 1998-04-02 Diatech Pty Ltd V-like domain binding molecules
CN101818145A (zh) 1998-03-20 2010-09-01 联邦科学和工业研究组织 控制基因表达
DK1068311T3 (da) 1998-04-08 2011-08-08 Commw Scient Ind Res Org Fremgangsmåder og midler til opnåelse af modificerede fænotyper
ATE370961T1 (de) 1998-05-06 2007-09-15 Genentech Inc Reinigung von antikörpern durch ionenaustauschchromatographie
AU776910B2 (en) 1998-12-08 2004-09-23 Merck Patent Gesellschaft Mit Beschrankter Haftung Modifying protein immunogenicity
US7115396B2 (en) 1998-12-10 2006-10-03 Compound Therapeutics, Inc. Protein scaffolds for antibody mimics and other binding proteins
JP2000319298A (ja) 1999-03-04 2000-11-21 Seibutsu Bunshi Kogaku Kenkyusho:Kk 蛋白質複合体の結晶、構造座標、及び構造座標の使用
US6326193B1 (en) 1999-11-05 2001-12-04 Cambria Biosciences, Llc Insect control agent
US7108852B2 (en) * 2000-03-20 2006-09-19 Warner-Lambert Company Llc Methods of treating inflammation using antibodies to M-CSF
EP1332209B1 (en) 2000-09-08 2009-11-11 Universität Zürich Collections of repeat proteins comprising repeat modules
EP1355919B1 (en) 2000-12-12 2010-11-24 MedImmune, LLC Molecules with extended half-lives, compositions and uses thereof
US8178098B2 (en) 2001-04-03 2012-05-15 National Jewish Health Method to inhibit airway hyperresponsiveness using aerosolized T cell receptor antibodies
JP4369662B2 (ja) 2001-04-26 2009-11-25 アビディア インコーポレイテッド 単量体ドメインのコンビナトリアルライブラリー
AUPR544401A0 (en) 2001-06-04 2001-06-28 Bischof, Robert Juergen Animal model for allergy
US7501494B2 (en) 2003-01-15 2009-03-10 United Biomedical, Inc. Designed deimmunized monoclonal antibodies for protection against HIV exposure and treatment of HIV infection
AU2004245038A1 (en) 2003-06-02 2004-12-16 Alexion Pharmaceuticals, Inc. De-immunized anti-CD3 antibody
CA2531238C (en) 2003-07-04 2015-02-24 Affibody Ab Polypeptides having binding affinity for her2
WO2005019255A1 (en) 2003-08-25 2005-03-03 Pieris Proteolab Ag Muteins of tear lipocalin
BRPI0417302A (pt) 2003-12-05 2007-03-06 Compound Therapeutics Inc inibidores de receptores de fator de crescimento endotelial vascular do tipo 2
DK1751181T3 (da) 2004-06-02 2012-11-26 Adalta Pty Ltd BINDINGSDELE, DER ER BASERET PÅ HAJ IgNAR-DOMÆNER
JP4958555B2 (ja) 2004-09-22 2012-06-20 協和発酵キリン株式会社 安定化されたヒトIgG4抗体
US20070135620A1 (en) 2004-11-12 2007-06-14 Xencor, Inc. Fc variants with altered binding to FcRn
WO2007025166A2 (en) 2005-08-25 2007-03-01 Repair Technologies, Inc. Devices, compositions and methods for the protection and repair of cells and tissues
CA2654894A1 (en) 2006-07-06 2008-10-01 Laboratoires Serono S.A. Csf3r polypeptides and uses thereof
AU2007283463B2 (en) 2006-08-11 2012-04-26 Csl Limited Treatment of pulmonary disease conditions
US20080199426A1 (en) 2007-01-11 2008-08-21 Sukhatme Vikas P Methods and compositions for the treatment and diagnosis of vascular inflammatory disorders or endothelial cell disorders
CL2008002782A1 (es) 2007-09-21 2009-07-31 Genentech Inc Anticuerpo anti-bv8 neutralizante; composicion que lo comprende; y su uso para tratar tumores en humanos previamente tratados con un antagonista del factor de crecimiento endotelial vascular.
JP5734201B2 (ja) 2008-12-19 2015-06-17 マクロジェニクス,インコーポレーテッド 共有結合型ダイアボディ及びその使用
JP2012515556A (ja) 2009-01-23 2012-07-12 バイオジェン・アイデック・エムエイ・インコーポレイテッド 低下したエフェクタ機能を有する安定化Fcポリペプチドおよび使用方法
FR2950381B1 (fr) 2009-09-18 2011-10-28 Snecma Turbomachine a helices non carenees contrarotatives
US8968731B2 (en) 2009-10-09 2015-03-03 Csl Limited Treatment of uveitis
AU2010311332B2 (en) 2009-10-30 2015-04-23 Albumedix Ltd. Albumin variants
WO2011103076A1 (en) 2010-02-16 2011-08-25 Medlmmune, Llc Hsa-related compositions and methods of use
EP2367000A1 (en) 2010-03-04 2011-09-21 Charité Universitätsmedizin Berlin High throughput analysis of T-cell receptor repertoires
CN102869777B (zh) 2010-04-02 2018-11-02 库尔纳公司 通过抑制集落刺激因子3(csf3)的天然反义转录物而治疗csf3相关疾病
AU2011319746B2 (en) 2010-10-27 2015-07-30 Celldex Therapeutics, Inc. Method of improving transplant function using soluble complement receptor type I (sCR1)
EP2675471A4 (en) 2011-02-15 2015-01-28 Medimmune Llc HSA-RELATED COMPOSITIONS AND USE PROCESSES
RU2605595C2 (ru) 2011-06-13 2016-12-20 СиЭсЭл Лимитид Антитела против g-csfr и их применение
HK1200842A1 (en) 2011-11-18 2015-08-14 Albumedix Ltd Proteins with improved half-life and other properties
US9050305B2 (en) 2012-03-29 2015-06-09 Chs Pharma, Inc. Treatment for ischemic stroke
CA2890766A1 (en) 2012-11-08 2014-05-15 Novozymes Biopharma Dk A/S Albumin variants
WO2014179657A1 (en) 2013-05-03 2014-11-06 Eleven Biotherapeutics, Inc. Albumin variants binding to fcrn
EP3063171B1 (en) 2013-11-01 2019-07-24 University Of Oslo Albumin variants and uses thereof
JP2017507939A (ja) 2014-02-21 2017-03-23 ジェネンテック, インコーポレイテッド 抗il−13/il−17二重特異性抗体及びその使用
EP3220952B1 (en) 2014-11-17 2021-04-21 CSL Limited Method of treating or preventing stroke
EP3445450A4 (en) 2016-04-21 2020-01-08 CSL Limited METHOD FOR TREATING OR PREVENTING LIVER DISEASES
US20210179721A1 (en) 2017-11-29 2021-06-17 Csl Limited Method of treating or preventing ischemia-reperfusion injury
KR20190073917A (ko) * 2017-12-19 2019-06-27 포항공과대학교 산학협력단 인터류킨-17 억제제 및 종양괴사인자-알파 억제제를 유효성분으로 포함하는 호중구성 폐 염증질환의 예방 또는 치료용 약학적 조성물
US12281160B2 (en) * 2018-03-23 2025-04-22 Csl Limited Method of treating asthma
RS67656B1 (sr) 2018-05-10 2026-02-27 Regeneron Pharma Formulacije koje sadrže visoke koncentracije fuzionog proteina vegf receptora
JP7503056B6 (ja) 2018-11-07 2024-07-16 メルク・シャープ・アンド・ドーム・エルエルシー 抗lag3抗体および抗pd-1抗体の共-製剤
BR112021010920A2 (pt) * 2018-12-04 2021-08-31 CSL Innovation Pty Ltd Método de tratamento de condições neutrofílicas
KR20220019806A (ko) * 2019-06-12 2022-02-17 씨에스엘 이노베이션 피티와이 엘티디 가용성 보체 수용체 1형 변이체 접합체 및 이의 용도
US20240002517A1 (en) * 2020-12-16 2024-01-04 CSL Innovation Pty Ltd Protein formulations and uses thereof

Similar Documents

Publication Publication Date Title
Achauer et al. Pulmonary complications of burns: the major threat to the burn patient
JP2020002144A (ja) 小児における急性呼吸促迫症候群の治療のための吸入一酸化窒素ガスを使用する方法
Petty et al. The adult respiratory distress syndrome: clinical features, factors influencing prognosis and principles of management
US20210309733A1 (en) Methods for treating coronavirus infection and resulting inflammation-induced lung injury
US20230130925A1 (en) Methods to prevent, ameliorate and treat complications from viral infections
WO2021191900A1 (en) Methods for treating infectious diseases caused by coronavirus
Sahu et al. A rare case of pneumopericardium secondary to COVID-19
US20220387455A1 (en) Treatment of moderate to severe influenza
MacDonnell et al. Adrenaline administered via a nebulizer in adult patients with upper airway obstruction
Patrucco et al. Current treatment challenges in the COVID-19 pandemic
Rubin et al. Pulmonary edema associated with child abuse: case reports and review of the literature
Takiguchi et al. Fulminant Mycoplasma pneumoniae pneumonia
Sugimoto et al. Humidifier use and prone positioning in a patient with severe COVID-19 pneumonia and endotracheal tube impaction due to highly viscous sputum
Flynn et al. Treatment of respiratory syncytial virus pneumonia in a lung transplant recipient: case report and review of the literature
Ferstenfeld et al. Recognition and treatment of adult respiratory distress syndrome secondary to viral interstitial pneumonia
Makkar et al. Respiratory management of adult patients with acute respiratory distress syndrome due to COVID-19.
US11278598B2 (en) Methods for treating diseases associated with respiratory viruses
TW202245799A (zh) 治療冠狀病毒感染及由其導致之發炎所誘發的肺損傷之方法
O'Brien et al. Interstitial viral pneumonitis complicated by severe respiratory failure: Successful management using intensive dehydration and steroids
Chan et al. In-hospital care of children with COVID‐19
Hitawala et al. Early Use of Tocilizumab May Prevent Clinical Deterioration in Select COVID-19 Patients: A Case Series
Raghavan et al. Hemopneumothorax in a COPD patient treated with noninvasive positive pressure ventilation: the risk of attendant anticoagulation
Tibby et al. Use of permissive hypercapnia in the ventilation of infants with respiratory syncytial virus infection
Krenn et al. Efficacy of solnatide to treat pulmonary permeability edema in SARS-CoV-2 positive patients with moderate to severe ARDS: A randomized controlled pilot-trial
Claydon et al. Varicella pneumonitis: a role for extra-corporeal membrane oxygenation?